UTMD

SALT LAKE CITY, UT / ACCESS Newswire / May 5, 2026 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty-one cents ($.31) per share of common stock payable on July 3, 2026 to stockholders of record at the close of business on June 17, 2026. This is a 1.6% increase over the dividend declared in the same quarter of the prior year. Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over a hundred countries around the world as the standard for obtaining optimal long-term outcomes for their patients. For more information about Utah Medical Products, Inc., visit UTMD's website at www.utahmed.com. Contact: Brian Koopman (801) 566-1200 SOURCE: Utah Medical Products, Inc. View the original press release on ACCESS Newswire

Shares of Utah Medical Products, Inc. UTMD have declined 4.3% since the company reported its earnings for the quarter ended March 31, 2026, underperforming the S&P 500 index, which rose 0.6% over the same period. Over the past month, however, the stock has gained 2.8%, still lagging the broader market’s 13.8% increase, indicating relatively muted investor sentiment toward the company’s recent performance. Utah Medical reported first-quarter 2026 earnings per share of 81.8 cents, which declined 11% from 91.9 cents in the prior-year quarter. Net sales fell 10.2% to $8.7 million from $9.7 million in the prior-year quarter. Net income decreased 14.4% to $2.6 million, and operating income dropped 18.7% to $2.6 million. Gross profit declined modestly by 4.6% to $5.3 million, reflecting some resilience in margins despite lower revenues. While overall sales contracted, profitability metrics showed mixed trends. Gross profit margin improved to 60.6% from 57% a year earlier, driven by a more favorable product mix and the absence of lower-margin sales to a former distributor in China. However, operating margin declined to 29.4% from 32.5%, and net income margin slipped to 29.9% from 31.3%, reflecting higher operating expenses and lower sales leverage. Geographically, domestic sales remained largely flat, declining just 0.4%, while international (outside the U.S.) sales dropped sharply by 23.4%. This decline was primarily due to the loss of sales to a previous Chinese distributor, which accounted for a significant portion of prior-year revenues. Segment-level trends were mixed. Direct domestic medical device sales fell 12.8%, and OEM sales dipped slightly, while domestic Filshie device sales surged 47.4%, partially offsetting broader weakness. Management noted that first-quarter results were broadly in line with previously communicated expectations for the full year but cautioned that quarterly comparisons may not fully reflect annual performance trends. The company emphasized that certain demand fluctuations, particularly in direct sales and Filshie device volumes, may reflect atypical quarterly patterns rather than structural changes. UTMD also highlighted its strong balance sheet, noting the continued absence of debt and increased cash balances despite ongoing share repurchases, dividend payments, and capital investments. Several factors weighed on the quarter’s perf...

SALT LAKE CITY, UT / ACCESS Newswire / April 23, 2026 / In the first calendar quarter (1Q) of 2026, Utah Medical Products, Inc. (Nasdaq:UTMD) attained financial results which were consistent with its previously announced projections for calendar year 2026. But because of the relatively short span of time, results for any given three-month period in comparison with a previous three-month period may not be indicative of comparative results for the year as a whole. Summary of results. The following is a summary comparison of 1Q 2026 with 1Q 2025 income statement measures: Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros. Currency amounts throughout this report are in thousands, except per share amounts and where noted. Consolidated sales in 1Q 2026 were $987 lower than in 1Q 2025. As expected and previously reported, UTMD did not have any 1Q 2026 sales to its previous largest medical device distributor of blood pressure monitoring kits in China, or to its previous OEM customer, PendoTECH. The combined sales to those two entities in 1Q 2025 were $857, representing 87% of the lower 1Q 2026 sales. Although overall domestic sales were about the same in both 1Q 2026 and 2025, sales outside the U.S. (OUS) excluding the China distributor were another $176 lower, due to lower Filshie Clip System sales OUS. Using the same foreign currency exchange (FX) rates for sales not invoiced in USD, i.e. in "constant currency" terms, OUS sales would have been an additional $169 lower because of a weaker USD. FX rates for income statement purposes are transaction-weighted averages. The average FX rates from the applicable foreign currency to USD during 1Q 2026 and 1Q 2025 follow: UTMD's 1Q 2026 GP at $5,282 was $256 lower than 1Q 2025 GP of $5,538. The 4.6% lower GP was less than the 10.2% decline in sales as a result of a more favorable product mix and a yearly one-time adjustment to standard costs which increased inventory value. Historically, sales to UTMD's largest OUS distributor in China had a significantly lower GP Margin (GPM), GP/Revenues, than UTMD's average GPM. Although manufacturing overhead costs were higher, which should lower the GPM when sales are lower, UTMD continues to effectively manage its variable manufacturing expenses. Consolidated wor...

MIDVALE, Utah (AP) — MIDVALE, Utah (AP) — Utah Medical Products Inc. (UTMD) on Thursday reported earnings of $2.6 million in its first quarter. On a per-share basis, the Midvale, Utah-based company said it had profit of 82 cents. The medical device maker posted revenue of $8.7 million in the period. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on UTMD at https://www.zacks.com/ap/UTMD

Shares of Utah Medical Products, Inc. UTMD have gained 2% since the company reported its fourth-quarter and full-year 2025 earnings. This outpaced the S&P 500 index’s modest 0.2% growth over the same period. Over the past month, UTMD shares have climbed 7.6%, significantly outperforming the S&P 500’s 1.5% increase. For the quarter ended Dec. 31, 2025, Utah Medical reported earnings per share (EPS) of 80.2 cents, which dropped 6.3% from 85.7 cents in the year-ago quarter. The year-over-year decline in EPS was less severe than the drop in net income and operating income, primarily due to a reduced number of outstanding shares following significant stock repurchases during the year. Revenues of $9 million reflected a 1.2% decline from $9.2 million in the same period a year ago. Gross profit slipped 1.1% to $5.26 million, down slightly from $5.32 million in the fourth quarter of 2024. Operating income fell more sharply, decreasing 16.7% year over year to $2.4 million from $2.9 million, due largely to higher operating expenses. Income before tax declined 14.1% to $3.1 million. Net income came in at $2.6 million, an 11.6% decline from $2.9 million in the prior-year quarter. Utah Medical Products, Inc. price-consensus-eps-surprise-chart | Utah Medical Products, Inc. Quote While sales were modestly lower, Utah Medical maintained a strong gross profit margin of 58.2%, nearly unchanged from 58.1% in the prior-year quarter. Operating income margin declined to 27% from 32%, and the net income margin fell to 28.4% from 31.7%. The company’s adjusted consolidated EBITDA for the quarter was $4 million, down 10% from $4.4 million a year ago. As a percentage of sales, EBITDA declined to 43.8% from 48.1%. Domestic U.S. sales in the fourth quarter declined 4.9% to $5.5 million from $5.7 million, with non-Filshie device sales accounting for the majority of the drop. OEM sales were down 31.5% year over year, while Filshie device sales in the U.S. increased 21.6%. Outside the U.S. (OUS) sales rose 4.9% to $3.6 million, largely due to favorable foreign exchange rates. On a constant currency basis, OUS sales were up only 0.5%, with weakness in direct-to-hospital Filshie sales partially offset by stronger distributor shipments. Management noted that the fourth quarter offered a more normalized comparison, as there were no sales to UTMD’s China distributor in either the fourth quarter...

SALT LAKE CITY, UT / ACCESS Newswire / February 4, 2026 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty-one cents ($.31) per share of common stock payable on April 3, 2026 to stockholders of record at the close of business on March 17, 2026. This is a 1.6% increase over the dividend declared in the same quarter of the prior year. Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over a hundred countries around the world as the standard for obtaining optimal long-term outcomes for their patients. For more information about Utah Medical Products, Inc., visit UTMD's website at www.utahmed.com. Contact: Brian Koopman (801) 566-1200 SOURCE: Utah Medical Products, Inc. View the original press release on ACCESS Newswire

SALT LAKE CITY, UT / ACCESS Newswire / January 29, 2026 / With some unexpected circumstances in 2025, Utah Medical Products, Inc (UTMD) did not achieve its beginning of year financial projections. Nevertheless the Company retained excellent profit margins, and increased its year-ending cash balances to $85.8 million despite paying $4.0 million in dividends to stockholders and repurchasing 4.5% (since the end of 2024) of its shares in the open market for $8.4 million. Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros. Currency amounts throughout this report are in thousands, except per share amounts and where noted. Overview of Results A summary comparison of 4Q and calendar year 2025 income statement category declines relative to the same periods of 2024 follows: Despite lower sales, profit margins in 4Q and year 2025 held up well compared to 4Q and year 2024, for reasons described later in this report: Because revenue results for any given three-month period in comparison with a previous three-month period are not indicative of comparative results for the year as a whole, investors should focus on the annual results described later in this release. Focusing on the causes of the $2.4 million consolidated worldwide (WW) decline in annual revenues in 2025, the lower sales can be explained by the three following categories: The OUS (Outside the U.S.) Distributor category (item 2 above) included UTMD's China distributor for blood pressure monitoring kits for which a non-changeable/noncancellable order at the beginning of 2025 for 2025 shipments was surprisingly cancelled in 3Q 2025, resulting in $431 lower revenues than had been committed, and $310 of the $471 lower OUS distributor sales compared to 2024. The decline in WW Filshie device revenues (item 3 above) can be divided into three parts: OUS Direct Filshie revenues were sales by UTMD subsidiaries directly to medical facilities in the UK, France, Ireland, Canada, Australia and New Zealand. In contrast to a sales increase in the U.S., OUS Filshie sales were significantly lower. Because of additional cost-of-living adjustments for employees in 2025 and continued inflation in raw material costs, UTMD realized an expected decrease in its 2025 gross profit margin compared to 2024. Neverthele...

MIDVALE, Utah (AP) — MIDVALE, Utah (AP) — Utah Medical Products Inc. (UTMD) on Thursday reported net income of $2.6 million in its fourth quarter. The Midvale, Utah-based company said it had net income of 80 cents per share. The medical device maker posted revenue of $9 million in the period. For the year, the company reported profit of $11.3 million, or $3.48 per share. Revenue was reported as $38.5 million. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on UTMD at https://www.zacks.com/ap/UTMD

SALT LAKE CITY, UT / ACCESS Newswire / November 4, 2025 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors has appointed Kevin C. Timken, Esq to its Board of Directors. Mr. Timken, who served as UTMD's outside legal counsel for over twenty years prior to his retirement in 2025, graduated with a J.D. degree from the University of Utah College of Law in 1997. The Board believes his robust understanding of the functional and strategic challenges that the Company faces will be integral for continuing UTMD's future excellent performance. In addition, the Board of Directors approved a quarterly cash dividend of thirty-one cents ($.31) per share of common stock payable on January 5, 2026 to shareholders of record at the close of business on December 16, 2025. This is a 1.6% increase over the prior regular quarterly cash dividend. Utah Medical Products, Inc., with particular interest in health care for women and their babies, develops, manufactures and markets a broad range of disposable and reusable specialty medical devices recognized by clinicians in over a hundred countries around the world as the standard for obtaining optimal long term outcomes for their patients. For more information about Utah Medical Products, Inc., visit UTMD's website at www.utahmed.com. Contact: Brian Koopman (801) 566-1200 SOURCE: Utah Medical Products, Inc. View the original press release on ACCESS Newswire

Shares of Utah Medical Products, Inc. UTMD have declined 4.1% since the company reported its earnings for the quarter ended Sept. 30, 2025. This compares to the S&P 500 index’s 2.8% growth over the same time frame. Over the past month, the stock has declined 7.1% compared with the S&P 500’s 3.1% growth. For the third quarter of 2025, Utah Medical reported an earnings per share (EPS) of 82 cents, which declined 19.9% from $1.025 in the prior-year quarter. The company witnessed a 1.9% decline in revenue to $9.8 million from $10 million in the prior-year quarter. Net income dropped by 26.2% to $2.6 million from $3.6 million. These results reflect a challenging operating environment marked by trade disruptions and a weaker sales pipeline. Utah Medical Products, Inc. price-consensus-eps-surprise-chart | Utah Medical Products, Inc. Quote Gross profit for the third quarter was down 3.4% year over year to $5.6 million, with a corresponding gross margin decline to 57.1% from 58%, reflecting both higher manufacturing overhead and increased tariffs, particularly on imported Filshie devices from Ireland. Operating income fell 21.9% to $2.6 million, yielding an operating margin of 26.6%, down from 33.4%. Adjusted EBITDA, a non-GAAP measure used by management to assess core operational performance, dropped 15.9% to $4.2 million in the quarter. Adjusted EBITDA margin contracted to 42.5% from 49.6%. These declines signal reduced profitability across operations, despite ongoing cost controls. Management attributed the disappointing quarter to an unexpected cancellation or delay of previously confirmed orders from two non-U.S. distributors. This resulted in a direct revenue loss of $0.6 million and triggered a $0.4 million bad debt provision, adversely impacting operating income. The cancellation from the China distributor, in particular, may signal a potential end to a two-decade-long business relationship. CEO Brian Koopman stressed that these disruptions had an outsized impact on the quarter, but noted that UTMD remains financially robust. UTMD also faced reduced sales from its former major OEM customer, PendoTECH, which fell to just $0.01 million in the quarter from $0.3 million a year earlier. However, the company noted that PendoTECH-related sales have almost bottomed out and may no longer significantly drag future performance. Several macro and operational factors play...

Utah Medical Products (UTMD) reported a net profit margin of 30.1% for the most recent period, down from 34.6% last year. Over the past five years, earnings have grown at an average annual rate of 2.2%, but the latest figures reveal negative earnings growth and tighter margins compared to the previous year. See our full analysis for Utah Medical Products. Next, we will see how these headline numbers match up with the key narratives around the stock, looking for places where the earnings meet or defy expectations. Curious how numbers become stories that shape markets? Explore Community Narratives Utah Medical Products' current share price is $60.43, which is significantly below its DCF fair value estimate of $112.61. This gap of more than 45% stands out even compared to many defensive healthcare stocks. The prevailing market view puts the valuation gap in focus, suggesting that the company's reputation for high quality earnings and a perceived discount to fair value are appealing to value-minded investors. This discount persists despite recent negative earnings growth and margin tightening, indicating the market may be pricing in caution over profitability trends. Even with profitability concerns, the DCF figure offers substantial headroom for a re-rating if fundamentals stabilize or improve. The company's Price-to-Earnings ratio is 16.7x, lower than the US Medical Equipment industry average of 30.3x but higher than its direct peer average of 12.3x. This places it in a middle ground that balances sector and peer benchmarks. According to the prevailing market perspective, this valuation position signals that while Utah Medical Products is seen as cheaper than most of its industry, it is not necessarily trading at the absolute lowest end given its track record of steady, high-quality earnings. The current ratio may point to expectations of resilience rarely found in lower-valued peers. This mid-tier multiple may reflect both the firm’s attractive dividend and the recent decline in profit margins. No material risks are flagged in the available financial statements, while the company is explicitly characterized as offering an attractive dividend. This is one of few concrete rewards called out in the report. The latest prevailing view highlights that this clean risk profile, when combined with reliable dividends, makes UTMD attractive for defensively oriented inve...

MIDVALE, Utah (AP) — MIDVALE, Utah (AP) — Utah Medical Products Inc. (UTMD) on Thursday reported profit of $2.6 million in its third quarter. On a per-share basis, the Midvale, Utah-based company said it had profit of 82 cents. The medical device maker posted revenue of $9.8 million in the period. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on UTMD at https://www.zacks.com/ap/UTMD